Phase 2Not yet recruiting
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma (NF118)
- Sponsor
- University of Alabama at Birmingham (Academic or other)
- Enrolment
- 55 planned
- Conditions
- Neurofibromatosis 1 (NF1)
- Interventions
- mirdametinib with radiation; mirdametinib
- Ages
- children, adults, older adults
- Registry
- NCT07521657
From the registry
This is a phase 2, open label, parallel multi-arm study of mirdametinib in combination with radiation in participants with recurrent sporadic glioblastoma (GBM) harboring NF1 alterations (Cohort 1); participants with NF1 with a newly diagnosed GBM (Cohort 2); mirdametinib alone in other NF1-associated High-Grade Gliomas (Cohort 3).
Primary outcomes
- Cohort 1
- Cohort 2
- Cohort 3